Q4 2023 · 13F-HR
Fairmount Funds Management LLCholdings as filed
Filed 2024-02-14 · accession 0001104659-24-023531
$946.5M
Reported value
16
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $187.8M | 19.8% | 2,360,077 | Common | SOLE |
| 45253H101 | IMGNEUR | IMMUNOGEN INC | $175.8M | 18.6% | 5,929,592 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $141.6M | 15.0% | 1,924,626 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $82.2M | 8.68% | 2,941,176 | Common | SOLE |
| 75525N107 | — | RAYZEBIO INC | $77.5M | 8.18% | 1,245,929 | Common | SOLE |
| G5269C101 | — | KINIKSA PHARMACEUTICALS LTD | $50.6M | 5.34% | 2,883,221 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $43.0M | 4.54% | 112,903 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $29.8M | 3.15% | 1,369,623 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $29.5M | 3.12% | 2,131,369 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $27.3M | 2.88% | 3,554,129 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $20.9M | 2.21% | 3,558,975 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $20.1M | 2.12% | 1,928,503 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $19.7M | 2.08% | 717,254 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $19.3M | 2.04% | 1,393,329 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $13.2M | 1.40% | 2,040,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $8.1M | 0.86% | 378,421 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.